Ceribell Reports Third Quarter 2026 Financial Results

Ceribell posts 30% revenue growth but losses deepen as investments accelerate.

What the company is saying

Ceribell emphasizes robust top-line momentum, reporting $29.3 million in Q3 2026 revenue, up 30% from $22.6 million a year earlier. The company highlights record account additions, with 747 active accounts and 35 net new customers in the quarter, and claims double-digit same-store utilization growth. Management, led by CEO Jane Chao, frames the narrative as one of durable growth, citing a 90% gross margin—improved from 88%—attributed to manufacturing cost reductions and the new Vietnam production line. The company spotlights the full commercial launch of its delirium monitoring solution and recent FDA 510(k) clearance for new EEG analytics as strategic milestones. Ceribell raises its full-year 2026 revenue guidance to $115–117 million, projecting 29–31% growth, while clarifying this excludes material contributions from neonate, pediatric, or delirium products. The tone is confident, focusing on operational achievements and future positioning for 2027, but operational expense escalation and ongoing losses are acknowledged as part of the investment phase.

What the data suggests

The Q3 2026 results show total revenue of $29.3 million, up 30% from $22.6 million in Q3 2025, with product revenue rising 31% to $22.2 million and subscription revenue up 28% to $7.1 million. Gross profit increased to $26.3 million from $19.9 million, and gross margin improved to 90% from 88%, reflecting manufacturing efficiencies, notably from the Vietnam line. Operating expenses rose sharply by 36% to $46.9 million, driven by commercial expansion, R&D, and legal costs, outpacing revenue growth. Net loss widened to $21.4 million ($0.55 per share) from $13.5 million ($0.37 per share), and adjusted EBITDA loss increased to $12.1 million from $9.2 million. Cash, cash equivalents, and marketable securities stood at $117.5 million as of September 30, 2026, with an additional $60 million credit facility secured in August and $25 million of uncommitted capital potentially available. The company’s updated full-year guidance of $115–117 million in revenue implies continued strong growth but does not address the path to profitability. Operational claims about same-store utilization and pilot success are not quantified. The disclosures are comprehensive for financials but less so for granular operational metrics.

Analysis

The announcement is generally positive in tone, highlighting strong revenue growth (30% YoY), gross margin improvement, and new product launches. These claims are supported by detailed financial disclosures, including revenue, gross profit, gross margin, net loss, and adjusted EBITDA. However, the company remains unprofitable, with net and adjusted EBITDA losses widening year-over-year, and operating expenses rising faster than revenue. Some operational claims, such as 'double-digit same-store utilization growth' and the impact of the Vietnam manufacturing line, are asserted without precise quantitative detail. The forward-looking elements (raised revenue guidance, product pipeline) are proportionate and not excessive, but the narrative somewhat overemphasizes momentum given persistent losses. The majority of key claims are realised, with only a minority being forward-looking projections.

Risk flags

• ●Sustained net and adjusted EBITDA losses indicate ongoing cash burn, with Q3 2026 net loss at $21.4 million and adjusted EBITDA loss at $12.1 million. This raises concerns about the timeline to profitability and the need for continued external funding if losses persist.
• ●Operating expenses are rising faster than revenue, up 36% year-over-year to $46.9 million, driven by commercial, R&D, and legal investments. If expense growth is not contained, margin improvements may not translate to improved bottom-line performance.
• ●The company’s manufacturing and supply chain depend on third-party vendors in China and Vietnam, exposing Ceribell to geopolitical, regulatory, and supply chain risks that could disrupt operations or impact cost structure.
• ●Some operational claims, such as double-digit same-store utilization growth and the impact of manufacturing initiatives, are asserted without precise quantitative backing, making it difficult to independently verify the sustainability and magnitude of these drivers.
• ●The new credit facility provides $60 million in committed capital, but reliance on debt increases financial leverage and could constrain future flexibility if cash flow does not improve.

Bottom line

Ceribell delivers strong revenue growth and margin expansion in Q3 2026, but losses are widening as the company invests heavily in commercial infrastructure, R&D, and legal actions. The balance sheet remains solid with $117.5 million in cash and marketable securities and a new $60 million credit facility, providing near-term liquidity. However, the path to profitability is not defined, and operating expenses are rising faster than revenue, raising questions about scalability and long-term financial sustainability. Operational claims about utilization and manufacturing gains lack detailed quantification, limiting independent assessment of their impact. Investors should focus on whether Ceribell can translate revenue momentum into operating leverage and narrow losses in coming quarters. The most important takeaway is that while top-line growth is robust, the company must demonstrate expense discipline and a credible route to profitability to justify continued investment.

Announcement summary

(NASDAQ:CBLL) Ceribell, Inc. reported total revenue of $29.3 million for the third quarter ended September 30, 2026, representing a 30% increase compared to $22.6 million in the same period of 2025. The company ended the quarter with 747 total active accounts, adding a record 35 net new customers during the quarter. Ceribell achieved double-digit year-over-year same-store utilization growth and a gross margin of 90%. The company announced the full launch of its delirium monitoring solution following a successful commercial pilot and received U.S. FDA 510(k) clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis. Product revenue for Q3 2026 was $22.2 million, up 31% from $17.0 million in Q3 2025, while subscription revenue was $7.1 million, up 28% from $5.6 million in Q3 2025. Gross profit for the quarter was $26.3 million, compared to $19.9 million in Q3 2025. Gross margin improvement was attributed to manufacturing cost reduction initiatives and the introduction of a fully operational manufacturing line in Vietnam. Operating expenses for Q3 2026 were $46.9 million, up from $34.6 million in Q3 2025, primarily due to investments in the commercial organization, research and development, algorithm development, clinical studies, stock-based compensation, and legal costs related to intellectual property enforcement. Net loss for Q3 2026 was $21.4 million, or $0.55 per share, compared to a net loss of $13.5 million, or $0.37 per share, in Q3 2025. Adjusted EBITDA loss for Q3 2026 was $12.1 million, compared to $9.2 million in Q3 2025. As of September 30, 2026, cash, cash equivalents, and marketable securities totaled $117.5 million. In August 2026, Ceribell entered into a new credit facility providing access to up to $60 million in committed capital, including a $30 million term loan and a $30 million revolving credit facility, with an additional $25 million of uncommitted capital available at the lender’s discretion. The company raised its full-year 2026 revenue guidance to a range of $115 million to $117 million, representing growth of approximately 29% to 31% over the prior year. The updated guidance does not include material contributions from neonate, pediatric, or delirium products. Manufacturing operations rely on third-party manufacturers and suppliers in China and Vietnam. The company’s balance sheet as of September 30, 2026, showed total assets of $156,370,000 and total liabilities of $38,833,000. Common stock had a par value of $0.001, with 38,820,703 shares issued and outstanding as of September 30, 2026. Adjusted EBITDA for the nine months ended September 30, 2026, was a loss of $33,135,000. The company’s net loss for the nine months ended September 30, 2026, was $60,357,000. Ceribell’s operating lease liabilities as of September 30, 2026, were $1,218,000 (current) and $432,000 (long-term). The company’s manufacturing line in Vietnam contributed to cost reductions and gross margin improvements.

Disagree with this article?